Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data BiomX Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
9.14
13.5
19.4
22.7
16.2
16.7
24.7
21.3
General and administrative
3.36
8.72
9.32
11.3
9.46
8.65
11.8
9.63
Operating expenses
0.38
Operating income
-12.5
-0.4
-22.2
-30.3
-35.5
-27.2
-25.3
-44.5
-41.5
Interest expense
0.7
2.07
2.4
0.87
0.02
Interest income
0.89
Other non-operating income
0
0.9
1.25
-0.92
-0.72
Pre-tax income
-12.7
0.48
-20.6
-30.1
-36.2
-28.3
-26.1
-17.7
-36.2
Income tax
0.14
0.07
0.07
0.02
0.01
0.01
Net income
-12.7
0.35
-20.6
-30.1
-36.2
-28.3
-26.2
-17.7
-36.2
EBITDA
-12.3
-21.9
-31.6
-37.2
-24.7
-24.5
-42.7
-38.5
EPS, basic
1,322.00
-26.03
635.16
225.61
241.22
164.87
88.51
25.37
22.19
EPS, diluted
1,322.00
-26.03
635.16
225.60
241.22
164.87
88.51
58.31
22.19
Shares, basic (weighted)
0.01
0.01
0.03
0.13
0.15
0.17
0.3
0.7
1.63
Shares, diluted (weighted)
0.01
0.01
0.03
0.13
0.15
0.17
0.3
0.76
1.63
Balance sheet
FY2019
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
8.6
0.7
72.3
36.5
62.1
31.3
14.9
16.9
4.36
Short-term investments
31.1
10
19.9
2
Other current assets
0.14
2.07
3.58
3.54
2.59
1.77
2.71
0.46
Total current assets
39.9
0.74
84.5
60.7
66.6
36.9
17.6
20.5
5.58
Property, plant and equipment
0.89
1.88
2.23
5.69
4.79
3.9
5.05
Lease right-of-use assets
1.15
4.43
4.14
3.86
3.5
5.46
Goodwill
0.8
Intangible assets
3.04
1.52
Long-term investments
70
70.9
Total assets
45.3
71.6
92.1
70.4
78
45.5
25
43.2
5.78
Accounts payable
0.19
3.25
2.32
2.8
0.82
1.38
1.88
3.12
Accrued liabilities
3.77
0.72
Deferred revenue
1.98
Short-term debt
0.38
0.86
0.82
4.28
5.79
Total current liabilities
1.64
0.37
6.22
7.16
11
7.94
11.2
8.27
6.38
Long-term debt
0.86
5.03
14.4
10.6
5.4
Lease liabilities
5.03
4.79
3.8
3.24
8.45
Other non-current liabilities
0.7
0.22
0.19
0.16
0.08
Total liabilities
0.54
0.87
7.67
12.9
30.5
24.5
21.9
19.1
7.09
Total debt
1.23
5.9
15
15
11.2
Paid-in capital
64.4
4.65
127
130
156
158
166
186
197
Retained earnings
0.01
0.35
-137
-163
-181
-217
Other comprehensive income
-21.6
-42.2
-72.3
-108
-137
Shareholders' equity
42.8
38.2
84.5
57.5
47.5
21
3.08
24.1
-1.3
Total equity
42.8
38.2
84.5
57.5
47.5
21
3.08
24.1
-1.3
Total liabilities and equity
45.3
71.6
92.1
70.4
78
45.5
25
43.2
5.78
Shares outstanding
0.01
0.01
0.13
0.13
0.17
0.17
0.27
1.02
1.59
Cash flow statement
FY2019
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-12.7
0.35
-20.6
-30.1
-36.2
-28.3
-26.2
-17.7
-36.2
Depreciation and amortization
0.21
0.32
-1.32
-1.77
2.52
0.87
1.8
2.92
Stock-based compensation
0.95
0.94
2.89
3.24
1.53
1.06
1.85
2.09
Deferred income tax
-0
Change in payables
-0.23
0.23
3.06
-0.86
Cash from operations
-11.3
-0.2
-17.6
-24.4
-27.6
-29.1
-21.3
-37
-26.4
Capital expenditures
-0.14
-1.31
-1.01
-3.68
-0.11
-0.05
-0.03
-0
Acquisitions
0.66
Purchases of investments
-13.5
Cash from investing
-30
-70
19.7
-10.9
16.2
-2.11
1.95
0.72
0.11
Debt issued
14.2
Debt repaid
-4.25
-10.7
Stock issued
1.8
-0.1
5.19
0.02
7.49
1
Cash from financing
43
70.9
61.6
0.13
37.3
0.29
2.9
38.4
13.2
Exchange rate effect
-0.03
0.11
0.01
0
0.07
Net change in cash
1.7
0.7
63.7
-35.2
25.9
-30.9
-16.4
2.11
-13.1
Free cash flow
-11.4
-18.9
-25.5
-31.3
-29.2
-21.3
-37
-26.4
Interest paid
0.4
1.55
1.87
1.44
0.02
Income taxes paid
0.07
0.07
0.05
0.01
0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.85 on September 10, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-418.7%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-161.4%
Net income / average total assets.
Return on invested capital (ROIC)
-242.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
EPS growth, 1y
-61.9%
EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y
-48.8%
Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y
-37.1%
Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-105.4%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-86.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-49.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-39.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
115.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
111.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
65.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.24x
Current assets / current liabilities.
Quick ratio
0.09x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.06x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.02x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
0.9%
Total debt / total assets.
Liabilities / assets
37.5%
Total liabilities / total assets.
Net debt
-$325.0K
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$1.76
Cash from operations / diluted weighted shares.
Book value per share
$0.86
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
4.52x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.52x
Market cap / tangible book value, when positive.
Earnings yield
-92.6%
Net income / market cap (the inverse of P/E).
Was BiomX Inc. profitable in fiscal 2025?
No. It reported a net loss of $36.2M.
How much free cash flow did BiomX Inc. generate in fiscal 2025?
Cash from operations of $26.4M minus capital expenditures of $2.0K left free cash flow of -$26.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.